NasdaqCM:BLTEPharmaceuticals
A Look At Belite Bio (BLTE) Valuation After Wider First Quarter Net Loss And Mixed Share Price Moves
Belite Bio (BLTE) recently posted a first quarter net loss of US$26.94 million, wider than the prior year, a result that appears central to the stock’s recent move and investor discussion.
See our latest analysis for Belite Bio.
The first quarter loss came as the stock showed mixed momentum, with a 1-day share price return of 4.16% and a 7-day share price return of 2.60%, but a 90-day share price return down 22.23%, set against a very large 3-year total shareholder return of about 7x.
If...